WG
OCUL icon

Winton Group’s Ocular Therapeutix OCUL Stock Holding History

Winton Group’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$526K Buy
+62,100
New +$592K 0.02% 695

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Winton Group's OCUL Position: Q1 2026 in Review

Winton Group opened a new position in Ocular Therapeutix (OCUL) in Q1 2026: 62,100 shares worth $526K. The stake represents 0.02% of the portfolio and ranks #695 among its holdings.

269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Winton Group held 62,100 shares of Ocular Therapeutix worth $526K as of Q1 2026.
  • Ocular Therapeutix was a new Winton Group position in Q1 2026.
  • Ocular Therapeutix made up 0.02% of Winton Group's portfolio in Q1 2026, its #695 holding.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.